This study aimed to compare the efficacy and safety of Lenvatinib combined with programmed cell death protein-1 inhibitor plus transarterial chemoembolization or hepatic arterial infusion chemotherapy in patients with hepatocellular carcinoma with portal vein tumor thrombus.<h4>Method</h4>We searched PubMed, Embase and the Cochrane Library for studies. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.